PHASE-II EVALUATION OF MITOXANTRONE PLUS CISPLATINUM IN PATIENTS WITH ADVANCED BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY

被引：5
|
作者：
ATIBA, JO
GREEN, SJ
HYNES, HE
OSBORNE, CK
MILLER, TP
DAVIDNER, M
机构：
[1] UNIV CALIF IRVINE,COLL MED,IRVINE,CA 92717
[2] SW ONCOL GRP,CTR STAT,SEATTLE,WA
[3] WICHITA CCOP,WICHITA,KS
[4] UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX
[5] UNIV ARIZONA,ARIZONA CANC CTR,TUCSON,AZ 85724
[6] KANSAS CITY CLIN ONCOL PROGRAM,KANSAS CITY,MO
来源：
INVESTIGATIONAL NEW DRUGS | 1994年 / 12卷 / 02期
关键词：
CISPLATINUM; MITOXANTRONE; BREAST CANCER; PHASE I-II TRIAL;
D O I：
10.1007/BF00874442
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m(2) to 12.0 mg/m(2)) and cis-platinum (100 mg/m(2)) in 30 patients with advanced breast cancer as second-line therapy. There were 2 partial responses in 29 eligible patients. Toxicity was considerable, with 27 patients having grade 3 or 4 toxicity. Grade 3-4 toxicity included vomiting, thrombocytopenia, granulocytopenia, leukopenia and anemia. The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer.
引用
收藏
页码：129 / 132
页数：4
相关论文
共 50 条
  • [1] PHASE-II EVALUATION OF MITOXANTRONE IN ADVANCED PANCREATIC-CARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    TAYLOR, SA
    FLEMING, T
    VONHOFF, DD
    MCCRACKEN, JD
    BUKOWSKI, RM
    TALLEY, RW
    NATALE, RB
    GUY, JT
    SAMLOWSKI, WE
    COSTANZI, JH
    INVESTIGATIONAL NEW DRUGS, 1990, 8 (01) : 77 - 80
  • [2] PHASE-II TRIAL OF PIROXANTRONE IN METASTATIC BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    RAVDIN, PM
    GREEN, S
    DOROSHOW, JH
    MARTINO, S
    INVESTIGATIONAL NEW DRUGS, 1994, 12 (04) : 333 - 336
  • [3] PHASE-II STUDY OF L-ALANOSINE (NSC-153353) IN PATIENTS WITH ADVANCED BREAST-CANCER - A SOUTHWEST ONCOLOGY GROUP-STUDY
    VONHOFF, DD
    GREEN, SJ
    NEIDHART, JA
    FABIAN, C
    BUDD, T
    BOYD, JF
    OSBORNE, CK
    INVESTIGATIONAL NEW DRUGS, 1991, 9 (01) : 87 - 88
  • [4] SOUTHWEST-ONCOLOGY-GROUP STUDY OF MITOXANTRONE FOR TREATMENT OF PATIENTS WITH ADVANCED ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK
    MATTOX, DE
    VONHOFF, DD
    BALCERZAK, SP
    INVESTIGATIONAL NEW DRUGS, 1990, 8 (01) : 105 - 107
  • [5] MITOMYCIN-C AND MITOXANTRONE IN ANTHRACYCLINE-PRETREATED ADVANCED BREAST-CANCER PATIENTS - A PHASE-II STUDY
    PERRONE, F
    DEPLACIDO, S
    CARLOMAGNO, C
    GRAVINA, A
    DELAURENTIIS, M
    DELMASTRO, L
    GRIDELLI, C
    PAGLIARULO, C
    BIANCO, AR
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (03): : 218 - 222
  • [6] PHASE-II STUDY OF ORAL ETOPOSIDE FOR PATIENTS WITH ADVANCED BREAST-CANCER
    ATIENZA, DM
    VOGEL, CL
    TROCK, B
    SWAIN, SM
    CANCER, 1995, 76 (12) : 2485 - 2490
  • [7] A PHASE-II TRIAL OF MITOXANTRONE PLUS CYCLOPHOSPHAMIDE AND 5-FLUOROURACIL IN MODULATION WITH LEVO-FOLINATE FOR ADVANCED BREAST-CANCER PATIENTS
    LEONARDI, V
    MELI, M
    PALMERI, S
    RUSSO, A
    RINI, GB
    PERALTA, S
    RAUSA, L
    JOURNAL OF CHEMOTHERAPY, 1995, 7 (02) : 160 - 166
  • [8] MULTICENTER PHASE-II STUDY OF BREQUINAR SODIUM IN PATIENTS WITH ADVANCED BREAST-CANCER
    CODY, R
    STEWART, D
    DEFORNI, M
    MOORE, M
    DALLAIRE, B
    AZARNIA, N
    GYVES, J
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (06): : 526 - 528
  • [9] CURRENT TRIALS AND FUTURE-DIRECTIONS OF THE SOUTHWEST-ONCOLOGY-GROUP BREAST-CANCER COMMITTEE
    OSBORNE, CK
    CANCER, 1994, 74 (03) : 1135 - 1138
  • [10] DAILY ORAL MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN PATIENTS WITH ADVANCED BREAST-CANCER - A PHASE-II STUDY
    UNGER, C
    BECHER, R
    RIECHE, K
    WANDER, HE
    FRIEDRICH, G
    EDLER, L
    ONKOLOGIE, 1993, 16 (04): : 260 - 263
12345